Skip to main content
Top
Published in: Calcified Tissue International 1/2021

01-07-2021 | Osteoporosis | Letter to the Editor

The Role of Bone Biopsy in the Management of CKD-MBD and Osteoporosis

Author: Michael Pazianas

Published in: Calcified Tissue International | Issue 1/2021

Login to get access

Excerpt

In the Osteoporosis section of the article [1], the authors used the term “CKD-associated osteoporosis”. Arguably, on pathophysiological grounds, the contribution of the kidney in the development of osteoporosis is rather minimal. Indeed, Osteoporosis and Renal Osteodystrophy have different starting points and at some stage, converge and then continue their parallel course, a common finding in the 3rd age group of patients. The term “CKD-associated osteoporosis” adds to the confusion because, although histologically Osteoporosis and Renal Osteodystrophy are two distinct entities, technically, according to the 2000 NIH definition [2], both are Osteoporosis as both are “characterized by compromised bone strength predisposing to an increased risk of fracture”. (Fig. 1) Taking this further, according to the operational WHO definition which is based on the level of bone mass, measured as BMD and expressed as a T-score [3], any T-score of − 2.5 or lower is reported as Osteoporosis.
Literature
2.
go back to reference Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 2000 March 27–29; 17(1):1–45. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 2000 March 27–29; 17(1):1–45.
3.
go back to reference World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical report series 843. WHO, Geneva World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical report series 843. WHO, Geneva
Metadata
Title
The Role of Bone Biopsy in the Management of CKD-MBD and Osteoporosis
Author
Michael Pazianas
Publication date
01-07-2021
Publisher
Springer US
Published in
Calcified Tissue International / Issue 1/2021
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-021-00856-x

Other articles of this Issue 1/2021

Calcified Tissue International 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.